ADARx Pharmaceuticals, Inc.
Prices from Yahoo Finance's public feed. Some prices may be delayed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All ADRX news ›Retension Pharmaceuticals IPO priced at $12, raising $45 million
As seen on the 24/7 Wall St. homepage on October 9, 2026. Priced at $12, raising roughly $45 million Retension Pharmaceuticals priced at $12 a share, locking in about $45 million from 3.75 million shares with Leerink Partners and…
U.S. IPO Weekly Recap: Biotech IPOs Keep Flowing As Data Center Developer DayOne Joins The Pipeline
Seeking Alpha - Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion dollar data center developer, an emerging markets fintech, and a dental treatment company. - While market jitters have kept some IPO…
XORTX Moves to File Health Canada Trial Application for XRx-026 Gout Program
The latest update is out from XORTX Therapeutics Inc ( (XRTX) ). More about XORTX Therapeutics Inc Average Trading Volume: 201,993 Current Market Cap: $3.14M For detailed information about XRTX stock, go to TipRanks’ Stock Analysis page.
Eli Lilly-backed TRex Bio closes day flat after IPO
TRex Bio closes at $14 IPO price despite volatility in its trading debut. Read more here. - TRexBio(TRXB), which is backed by Eli Lilly (LLY), closed Friday, its first day of trading, at its IPO price, $14. - Shares opened at $13.50. They…
Aspen Neuroscience files for Nasdaq IPO with patient-derived Parkinson's cell therapy
As seen on the 24/7 Wall St. homepage on October 9, 2026. Aspen Neuroscience files for Nasdaq IPO as ASPE Aspen Neuroscience filed its S-1 to list on Nasdaq, giving public investors a rare direct shot at patient-derived cell therapy for…
Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share
(LLY:NYSE) Seeking Alpha - TRex Bio (TRXB) prices IPO at $14 per share, offering 8.33 million shares to the public, as the clinical-stage biotech company focuses on developing immunoregulatory medicines targeting tissue regulatory T-cell…
Atrium Therapeutics Raises $50 Million Private Placement To Advance Precision Cardiology Pipeline
Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a $50 million private placement to support development of its precision cardiology pipeline. Atrium agreed to sell approximately 5.17 million…
Vinci Pharmaceuticals Raises More Than $8 Million Series A To Advance EPIPLANT Platform
Vinci Pharmaceuticals closed a Series A financing of more than $8 million to advance development of its EPIPLANT sustained-release drug delivery platform for retinal diseases. The financing was led by Dynagrow Capital, with additional…
Bambusa Therapeutics pursues IPO to push eczema and inflammation drugs toward trials
Bambusa is going after unmet needs across skin, respiratory, gastroenterology and autoimmune conditions with long-acting bispecific antibodies. It assembled its lead programs by acquiring assets from a BioNTech SE unit. One candidate is…
Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline
Lycia Therapeutics' IPO, if fairly priced, is likely to attract strong interest, given early positive data and solid biopharma performance. Read more on LYCA. - Lycia Therapeutics is a clinical-stage biopharma targeting autoimmune and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com31
-
stocktitan.net20
-
tradingview.com15
-
seekingalpha.com9
-
pulse2.com8
Measured across the 4OverlandPark news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.